Involving Producing Or Treating Antigen Or Hapten Patents (Class 436/543)
  • Patent number: 5888754
    Abstract: This invention relates to a device comprising a hydrophobic solid support coated with a chemical that can capture bacterial lipopolysaccharides (LPS). This invention also relates to the use of such a device in an immunoassay for the detection of microorganisms. This invention also relates to the incorporation of such a device into a diagnostic kit.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: March 30, 1999
    Assignee: Kalyx Biosciences Inc.
    Inventors: Sithian Pandian, Eng Jom Aw, David I. Smith
  • Patent number: 5888728
    Abstract: The present invention encompasses a capture membrane comprising a porous filter membrane having a hapten bound directly or indirectly to the membrane wherein complexes formed by specific binding having an anti-hapten bound to a binding member of the specifically binding complex are removed from a solution by the hapten as the solution passes through the membrane. In the preferred embodiment biotin is the hapten and avidin or streptavidin is the anti-hapten.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 30, 1999
    Assignee: Molecular Devices Corporation
    Inventors: John D. Olson, Robert F. Zuk, Richard D. Armenta, Charles R. Burke, Viola T. Kung, Edward L. Sheldon
  • Patent number: 5869348
    Abstract: In accordance with the present invention, ELISA methods for the measurement of NO levels in mammalian body fluids utilizing monoclonal antibodies directed against dithiocarbamates and related iron complexes are described. It has been found that conjugation of dithiocarbamates to a macromolecule produces immunogenic dithiocarbamate-macromolecule derivatives. Such derivatives can be used for the production (e.g., in rodents) of monoclonal antibodies directed against different forms of dithiocarbamates (e.g., free dithiocarbamates, as well as complexes thereof with iron and, optionally, nitric oxide). In contrast, non-derivatized dithiocarbamates alone are not immunogenic. The simple, easy and non-invasive ELISA methods for measurement of NO levels in body fluids will find a variety of uses, e.g., for diagnosis and monitoring of NO overproduction that has been associated with many inflammatory and infectious diseases.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: February 9, 1999
    Assignee: Medinox, Inc.
    Inventor: Ching-San Lai
  • Patent number: 5869261
    Abstract: When measurement by a 1 step sandwich method is performed, a signal corresponding to a quantity of labeled antibodies A is sampled, the labeled antibodies being constrained in the vicinity of a surface of an optical waveguide (D) by an antigen-antibody reaction. A differential value by time at the beginning of the measurement and a signal corresponding to an extent of an immunological reaction at a time at which the signal becomes nearly stable are obtained based upon the sampled signals. The extent of the immunological reaction is then uniquely determined based upon the differential value by time and the signal corresponding to the extent of the immunological reaction.
    Type: Grant
    Filed: August 30, 1995
    Date of Patent: February 9, 1999
    Assignee: Daikin Industries, Ltd.
    Inventor: Kaori Tosa
  • Patent number: 5866335
    Abstract: The synthesis of 10,10'-substituted-9,9'-biacridine molecules and their derivatives is disclosed. These molecules are shown to catalyze the production of light by chemiluminescence in the presence of a signal solution having at a pH from about 10.0 to about 14.0, at a concentration effective for producing a chemiluminescent signal, a chelating agent, a sulfoxide, a reducing sugar, an oxidant or combination of oxidants, an alcohol and aqueous sodium tetraborate. These 10,10'-substituted-9,9'-biacridines are used alone or attached to haptens or macromolecules and are utilized as labels in the preparation of chemiluminescent, homogeneous or heterogeneous assays. They are also used in conjunction with other chemiluminescent label molecules to produce multiple analyte chemiluminescent assays.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: February 2, 1999
    Assignee: George W. Katsilometes
    Inventors: George W. Katsilometes, Pak T. Ho
  • Patent number: 5863401
    Abstract: Homogeneous competitive immunoassay methods for simultaneously detecting analytes using capillary electrophoresis and fluorescent detection systems are described. The methods are useful for detecting and/or quantitating the concentration of a plurality of drugs of abuse in a single urine sample using a single assay method.
    Type: Grant
    Filed: July 3, 1997
    Date of Patent: January 26, 1999
    Assignee: Beckman Instruments, Inc.
    Inventor: Fu-Tai A. Chen
  • Patent number: 5861262
    Abstract: An oligopeptide having an amino acid sequenceGlu Pro Gly Asn Ser Glu Ile Leu Pro Thr Leu Lysand variants thereof; immunogenic conjugates obtained therefrom; antibodies produced by means of said conjugates and which specifically recognize human plasma glutathione peroxidase (pl.GPx); methods for assaying human plasma glutathione peroxidase (pl.GPx); and assaying kits. The invention is useful in the medical diagnosis, treatment and monitoring of pathologic conditions induced by a variation in pl.GPx, for example, hepatic tumors, acute rejection of renal or hepatic graft, renal insufficiency and selenium deficiency.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: January 19, 1999
    Assignee: OXIS Isle of Man, Limited
    Inventors: Jean Chaudiere, Arnaud Lemainque, Patricia Malette
  • Patent number: 5858685
    Abstract: Benign prostatic hyperplasia-prostate specific antigen (BPH-PSA) and methods for its preparation are provided. Also provided are antibodies specific for BPH-PSA, and methods of their use in immunoassays for detecting the presence of BPH-PSA in a sample. The subject immunoassays find use in diagnosing the conditions associated with elevated serum PSA levels, such as prostate cancer and BPH.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: January 12, 1999
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas A. Stamey, Zuxiong Chen, John E. McNeal
  • Patent number: 5856112
    Abstract: A method for selectively inducing expression of biomarkers for urologic cancers, including prostate and bladder cancer, is disclosed. Tumor cells are cultured using a low shear rotational three-dimensional technique under conditions effective to induce said selective expression. The method is useful for diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: January 5, 1999
    Assignee: UroCor, Inc.
    Inventors: Garry M. Marley, Robert W. Veltri
  • Patent number: 5854009
    Abstract: Diagnostic/prognostic methods are provided for screening for pathologies wherein an alteration in estrogen metabolism is indicative of a pathology or a susceptibility thereto which comprise detecting and/or quantifying directly in tissues and body fluids of mammals abnormal levels of estrone metabolites and their glucuronide conjugates. Particularly preferred methods involve the use of the 16OHE1-, 2OHE1- or 2MeoE1-glucuronide fraction, i.e., the fraction which contains the metabolite and its 3-glucuronide conjugate. Methods of preparing reagents to detect said 16OHE1-, 2OHE1-, and 2MeoE1-glucuronide fraction in tissues and body fluids are disclosed as well as test kits for performing the disclosed assays.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: December 29, 1998
    Assignee: Immuna Care Corporation
    Inventor: Thomas L. Klug
  • Patent number: 5851781
    Abstract: The present invention discloses novel immunogens, antibodies prepared from such immunogens, and labeled reagents useful in immunoassays for the detection and quantification of testosterone in a test sample. Also disclosed are immunoassays using these reagents and methods for synthesizing these reagents. The immunoassays are preferably microparticle enzyme immunoassays (MEIAs) and fluorescence polarization immunoassays (FPIAs). Further disclosed are novel starting materials for making the above novel immunogens and labeled reagents. Methods for making the novel immunogens and labeled reagents from the novel starting materials are also disclosed.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: December 22, 1998
    Assignee: Abbott Laboratories
    Inventors: Maciej Adamczyk, Yon-Yih Chen, John A. Walling, Bryan D. James, Sharon G. Artrip
  • Patent number: 5849599
    Abstract: A method for making a preconjugate which includes immunogenic species of a polymorphic analyte. The method is carried out by reacting an activated binding moiety, and a polymorphic analyte at room temperature for between about 10 hours and about 60 hours. The attaching reaction results in an excess of the preconjugate which includes the immunogenic species of the polymorphic analyte. The preconjugate can be used to make an immunoreactive conjugate useful as a developer antigen in a competitive inhibition immunoassay for the polymorphic analyte.
    Type: Grant
    Filed: February 7, 1997
    Date of Patent: December 15, 1998
    Assignee: Beckman Instruments, Inc.
    Inventors: Chan S. Oh, Anthony K. Cheng, Josephine M. Michael, Thomas S. Dobashi
  • Patent number: 5840508
    Abstract: Compounds having detergent properties are disclosed. When a modifying reagent is brought into contact with these compounds, the detergent properties are decreased. These compounds are useful, for example, as solubilizing agents for microbial antigens and/or antibodies and for reversibly wetting hydrophobic surfaces. Accordingly, methods are disclosed for increasing the hydrophilic properties of a material, such as a microbial antigen and/or antibody, the methods generally comprising the steps of contacting the material with the compound having detergent properties and a modifiable group, and modifying the compound with a modifying reagent. Kits are also disclosed for use in accordance with this methodology.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: November 24, 1998
    Assignee: Behring Diagnostics GmbH
    Inventors: Arthur C. Switchenko, Nurith Kurn, Christian Neukom, Marcel Pirio, Donald E. Berger, Jr., Edwin F. Ullman
  • Patent number: 5840500
    Abstract: The present invention relates to novel tetrahydro-quinoline compounds of the following formula, libraries containing such compounds, and to the generation of such combinatorial libraries composed of such compounds: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and Y have the meanings provided.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: November 24, 1998
    Assignee: Trega Biosciences, Inc.
    Inventors: Yazhong Pei, John S. Kiely
  • Patent number: 5837251
    Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: November 17, 1998
    Assignee: Fordham University
    Inventor: Pramod K. Srivastava
  • Patent number: 5834206
    Abstract: There are disclosed hapten tracer complexes which, on the one hand, contain a hapten which is linked to an indicator component and, on the other hand, an antibody which can bind specifically to the indicator component. These hapten tracer complexes can be employed advantageously in immunoassays.
    Type: Grant
    Filed: December 7, 1995
    Date of Patent: November 10, 1998
    Assignee: Behring Diagnostics GmbH
    Inventors: Stephan Neuenhofer, Reinhard Kasmarker
  • Patent number: 5831012
    Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: November 3, 1998
    Assignee: Pharmacia & Upjohn Aktiebolag
    Inventors: Bjorn Nilsson, Per-.ANG.ke Nygren, Mathias Uhlen
  • Patent number: 5830770
    Abstract: Novel generic antibodies are provided that are specific to groups of organophosphates, particularly to a class of organophosphate pesticides in common usage. Further provided are compounds and methods for raising these antibodies, test kits containing them and methods for their use. The antibodies targeted at low molecular weight (i.e. below MW 1000) organophosphorous pesticides methacrifos, pirimphos methyl, etrimfos, fenitrothion, chlopyrifos methyl, dichlorovos and malathion. Preferred conjugates of the invention are of the formula (RO).sub.2 --P(S)--Z--?Y!-Protein wherein R is lower alkyl and Z is as O, S or --NH--, Y is a spacer group and "Protein" indicates a protein suitable for use in hapten protein conjugates for the purpose of raising antibodies and antisera. Typical and preferred proteins are bovine serum albumin, ovalbumin from chicken egg, keyhole limpet hemocyananin and mixtures of these.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: November 3, 1998
    Assignee: The Minister of Agriculture Fisheries and Food in Her Britannic Majesty's Government of the U.K. of Gt. Britain & N. Ireland
    Inventors: Wendy Alison Matthews, John Nicholas Banks, Mohamed Qasim Chaudhry
  • Patent number: 5827750
    Abstract: A method for the detection of the presence or absence of antibodies which bind to antigens of an NMA virus indicative of Chronic Fatigue Immune Deficiency Syndrome is disclosed. This method comprises contacting a solution containing antigens of an NMA virus with a biological sample of a patient and detecting the antibody-antigen complexes. Methods for detection of the presence or absence of antigens or nucleic acid sequences specific to an NMA virus are also disclosed. A substantially purified preparation of an NMA virus and a human cell line chronically infected with an NMA virus are also disclosed.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: October 27, 1998
    Assignee: Medical College of Wisconsin, Inc.
    Inventors: Sidney E. Grossberg, Vladimir M. Kushnaryov, L. William Cashdollar, Donald R. Carrigan, Konstance K. Knox
  • Patent number: 5824483
    Abstract: Combinatorial libraries of different-sequence peptide members is disclosed. The libraries are comprised of stabilized, alpha-helical polypeptides having a similar tertiary structure but different amino acid residues at specific, "variable" positions in the sequence. The polypeptides are stabilized through coiled-coil interactions with other .alpha.-helical polypeptides and/or via intrahelical lactam bridges. Also disclosed are methods for using such libraries to screen for selected macromolecular ligands.
    Type: Grant
    Filed: June 16, 1995
    Date of Patent: October 20, 1998
    Assignee: Pence Inc.
    Inventors: Michael E. Houston, Jr., Robert S. Hodges
  • Patent number: 5821342
    Abstract: The present invention provides a novel carbamazepine hydrazide compound suitable for covalent attachment to a polymer particle reagent, having the general formula ##STR1## The present invention also provides a novel carbamazepine acid compound suitable for attachment to proteins for the production of carbamazepine immunogens. The carbamazepine antigen of the present invention has the following general structure: ##STR2## where X is C=O, CH.sub.2 or SO.sub.2 ; Y is C=O, CH.sub.2, SO.sub.2 ; R is an alkyl and P is a protein or a hapten.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: October 13, 1998
    Assignee: Dade Behring Inc.
    Inventor: Chengrong Wang
  • Patent number: 5817770
    Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: October 6, 1998
    Assignee: Drug Abuse Sciences, Inc.
    Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
  • Patent number: 5807695
    Abstract: The invention is directed to monoclonal antibodies, their fragments, single chains and polypeptide mimics of their hypervariable regions which immunoreact with bare small moieties such as metallic cations and small organic molecules, the hybridomas for production of the monoclonal antibodies, immunogen compounds for developing the hybridomas, and methods for use of the monoclonal antibodies.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: September 15, 1998
    Assignee: Board of Regents of University of Nebraska
    Inventors: Fred W. Wagner, Dwane E. Wylie, Sheldon M. Schuster
  • Patent number: 5780243
    Abstract: The invention comprises a low temperature method for the in situ derivatization and coupling of thermally and hydrolytically labile organic compounds such as spectinomycin to immunogenic carrier substances. The compound coupled to the immunogenic carrier is utilized to produce antibodies selective for the organic compound. Such methods allow for the quantitative analysis of the target organic compound and may be competitive or non-competitive immunoassays in which the dose response is directly or indirectly proportional to the concentration of spectinomycin-related substances. Such assays may be used to detect the presence of or to quantitate the amount of the organic compound in a complex and varied immunological background such as a sample of a biomass material. Detection of organic compound in the sample occurs through binding to a specific antibody.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: July 14, 1998
    Assignee: Thaco Research, Ltd.
    Inventor: James D. Thacker
  • Patent number: 5776713
    Abstract: In general, the invention features a method of marking a product for identification in which a marker, composed of a low molecular weight hapten covalently bound to a compound, is associated with the product. Where the marker is non-deleterious to the product, inert with respect to the product, and not already associated with the product. The invention also features hapten markers produced by covalently binding a hapten to a functional monomer and subsequently polymerizing the hapten-labeled monomer to form a hapten-labeled polymer.
    Type: Grant
    Filed: August 16, 1994
    Date of Patent: July 7, 1998
    Assignee: Biocode Ltd.
    Inventors: Ronald Colin Garner, David J. Phillips, Timothy G. Wilkinson, Frank G. Angella, Erwin R. Dorland, Martin W. Stow
  • Patent number: 5776487
    Abstract: The present invention relates to the detection of a variety of analytes in a patient sample employing liposomes with associated ligand, where the ligand is capable of binding target analyte in that sample. In another aspect of the invention, the assays employ liposomes as a soluble support matrix where at least a portion of the support is associated with the ligand and the ligand is in a confirmation permitting it to bind to target analyte in a patient sample.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: July 7, 1998
    Assignee: Pasteur Sanofi Diagnostics
    Inventors: Nancy Maxfield Wilson, Catherine Larue
  • Patent number: 5776674
    Abstract: An optical trap is used to translate a particle through a thin film coating on an optically-flat surface. Preferably, the thin film coating is heterogeneous and the optical trap is used to move the particle through a succession of different regions of the thin film coating where different chemical, biochemical and/or biological processes take place. Examples of chemical, biochemical and/or biological processes that might be implemented in accordance with the invention include the following: oligonucleotide synthesis and sequencing, peptide synthesis and sequencing, carbohydrate synthesis and sequencing, combinatorial library synthesis and screening, conventional (i.e., Sanger or Maxam-Gilbert) DNA sequengcing, or single-molecule DNA sequencing. In one embodiment of the invention, reaction products are left behind as the particle is moved through the thin film coating. Advantageously, these products can be identified by suitable means.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 7, 1998
    Assignee: SEQ, Ltd
    Inventor: Kevin M. Ulmer
  • Patent number: 5770357
    Abstract: The present invention provides a method of diagnosing caprine arthritis-encephalitis virus infection (CAEV) in a human sample suspected of being infected with CAEV.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: June 23, 1998
    Inventors: Angeline Douvas, Glenn Ehresmann
  • Patent number: 5759779
    Abstract: A method of analyzing the sequence of a polynucleotide analyte. The method includes contacting the analyte with a position-addressable array of oligonucleotides, each anchored to a solid support and having a 5'proximal and 3'-distal orientation. The hybridized oligonucleotides are then extended by strand-directed polymerase, to produce labeled, extended oligonucleotides at positions of the array corresponding to sequence matches between the array oligonucleotides and analyte regions. The pattern of label in the array is used to analyze analyte sequence.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: June 2, 1998
    Inventor: Peter J. Dehlinger
  • Patent number: 5747047
    Abstract: The present invention is directed to novel purified and isolated mite allergens possessing mite allergen activity with a molecular weight of about 94,000, about 40,000, about 16,000 or about 14,000 as determined by SDS-PAGE, which can be isolated from extracts of mite, and to a process for producing such mite allergens. The purified and isolated mites allergens of the present invention are useful as a pharmaceutical and a diagnostic composition for mite allergic diseases.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: May 5, 1998
    Assignees: Fumakilla Ltd., Hiroshima University
    Inventors: Satoru Oka, Kazuhisa Ono, Seiko Shigeta, Takeshi Wada
  • Patent number: 5738996
    Abstract: A combinatorial library composition and method for using the library to construct oligomers effective to bind to a selected ligand is disclosed. The library composition includes at least two sets of ar oligomer libraries, each library set having selected oligomer subunit positions filled by known subunits, and other subunit positions containing permutations of subunits. In the selection method, oligomers from each library set are identified, and a new permutation library formed of subunits corresponding to the highest binding affinity oligomers in each library is screened for binding affinity to the selected ligand.
    Type: Grant
    Filed: June 15, 1994
    Date of Patent: April 14, 1998
    Assignee: Pence, Inc.
    Inventors: Robert S. Hodges, Randall T. Irvin, Arne Holm, Wah Y. Wong, Hasmukh B. Sheth, Devon L. Husband
  • Patent number: 5728589
    Abstract: The use of an antigen (or antibody) previously modified with a hapten makes the immunoassay of a trace component (analyte) on the basis of a change of turbidity or scattered light intensity caused by antigen-antibody reaction rapid and easy with high accuracy and high reproduction.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: March 17, 1998
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Yoshihiro Ushio, Katsuji Aoki
  • Patent number: 5728519
    Abstract: The present invention provides a method of classifying an unclassified live poliovirus vaccine as having an acceptable or unacceptable level of neurovirulence, comprising, prior to vaccine administration, the steps of: a) selectively amplifying a region of an unclassified poliovirus vaccine genome containing a nucleotide position predictive for increased neurovirulence using selectively mismatched primers, whereby a restriction endonuclease site in the selectively amplified region is created by introducing a site-specific mutation into the amplified region; b) digesting an amount of the amplified region with a restriction endonuclease that specifically cleaves the amplified sequences in revertant viruses which contain a reversion at the nucleotide position predictive for increased neurovirulence; c) digesting an amount of the amplified region with a restriction endonuclease that specifically cleaves the amplified sequences in nonrevertant viruses which contain the nucleotide position predictive for increased
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: March 17, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Inessa S. Levenbook, Konstantin M. Chumakov, Laurie P. Norwood, Igor Roninson
  • Patent number: 5721095
    Abstract: A method for producing an improved solid phase antigenic reagent useful in an immunoassay for detecting antibodies specific for a virus, such as the human immunodeficiency virus, is disclosed which comprising the addition to a natural viral lysate a synthetic or recombinant viral protein or peptide. Also provided is an improved immunoassay utilizing the solid phase antigenic reagent.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 24, 1998
    Assignee: Genelabs Diagnostics Pte Ltd.
    Inventors: Lily Chan, Yoke Wah Sum, May Fong Yin, Lee Fang Lim
  • Patent number: 5714314
    Abstract: A hepatitis C virus antigen polypeptide having a molecular weight of approximately 22 kilodaltons expressed from a hepatitis C virus structural gene region; a production method for a hepatitis C virus antigen polypeptide having a molecular weight of 22 kilodaltons and/or a peptide related thereto, wherein an expression vector having inserted thereinto a cDNA fragment of a hepatitis C virus structural gene region is inserted into a cultured cell line and the transfected cell line thus obtained is cultured; and a detection method for a hepatitis C virus antibody, wherein a hepatitis C virus antigen polypeptide is used as an antigen, and an antibody specific thereto is detected.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: February 3, 1998
    Assignees: National Institute of Health, Joe Chiba
    Inventors: Tatsuo Miyamura, Izumu Saito, Shizuko Harada, Yoshiharu Matsuura, Joe Chiba
  • Patent number: 5688696
    Abstract: A technique for generating nonrandom combinatorial libraries on solid phase supports in which each of a set of predetermined species of test compounds is present on a predetermined number of solid phase supports, preferably on only one, and each solid phase support has only a single species of test compound. Each of the predetermined species of test compounds is prepared with absolute certainty because the technique does not employ any random division of the solid phase supports. Rather, the method is based on the stepwise division of a continuous solid phase support matrix prior to each synthetic step in which more than one type of subunit is added. Non-limiting examples of matrices of the solid phase supports include polypropylene membranes, polytetrafluoropropylene membranes and cotton thread. The combinatorial libraries made by the technique are also disclosed.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: November 18, 1997
    Assignee: Selectide Corporation
    Inventor: Michal Lebl
  • Patent number: 5663074
    Abstract: This invention is directed to novel nucleophilic polysubstituted aryl acridinium conjugates and the methods for preparation thereof. The novel nucleophilic polysubstituted aryl acridinium conjugates are useful in biological assays, including novel assays for the determination of Vitamin B.sub.12, folate, cortisol, estradiol, and thromboxane B.sub.2.
    Type: Grant
    Filed: March 17, 1993
    Date of Patent: September 2, 1997
    Assignee: Chiron Diagnostics Corporation
    Inventor: Say-Jong Law
  • Patent number: 5660994
    Abstract: The invention relates to the identification of insoluble cytoskeletal proteins, or fragments thereof, which are characteristic of the origin of the tissue. The invention relates as well to the method for detecting such proteins by breaking down and solubilizing the protein for immunological detection and quantitation. The method allows detection of tissue lesions or other pathological foci and metastases.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: August 26, 1997
    Assignee: Progen Biotechnik GmbH
    Inventors: Gerda Bruder-Heid, Werner Wilhelm Franke
  • Patent number: 5656426
    Abstract: Novel acridinium esters that are useful, either alone or when incorporated into liposomes, as chemiluminescent agents in binding assays (e.g., immunoassays and gene probe assays) with improved-sensitivity are disclosed. In addition, the synthesis of these esters and their use in assays for detecting an analyte is described. In particular, assays for testosterone and the Rubella virus are disclosed.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: August 12, 1997
    Assignee: Chiron Diagnostics Corporation
    Inventors: Say-Jong Law, Chariklia Sotiriou-Leventis, Anand Natrajan, Qingping Jiang, Peter B. Connolly, John P. Kilroy, Constance R. McCudden, Stephen M. Tirrell
  • Patent number: 5650288
    Abstract: A method of assaying a sample of blood or blood components for the concentration of an immunophilin ligand comprising incubating the sample with a nonionic detergent and a protease, then inactivating the protease, and subsequently determining the concentration of the immunophilin ligand in the sample.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: July 22, 1997
    Inventors: Gordon D. MacFarlane, Todd L. Jensen
  • Patent number: 5646002
    Abstract: A method for treating serum samples to remove sialic acid from ligands to expose binding sites to enhance immunological binding, for use in assays and to generate novel anti-ligands is described. The method includes treatment of serum using neuraminidase.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: July 8, 1997
    Assignee: Oncogen Limited Partnership
    Inventors: Peter S. Linsley, Vincent Ochs, Diane Horn, Joseph P. Brown
  • Patent number: 5639624
    Abstract: The invention is directed to monoclonal antibodies, their fragments, single chains and polypeptide mimics of their hypervariable regions which immunoreact with bare small moieties such as metallic cations the hybridomas for production of the monoclonal antibodies, immunogen compounds for developing the hybridomas, and methods for use of the monoclonal antibodies.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: June 17, 1997
    Assignees: Board of Regents of the University of Nebraska, BioNebraska, Inc.
    Inventors: Fred W. Wagner, Dwane E. Wylie, Sheldon M. Schuster
  • Patent number: 5637508
    Abstract: Polymer or copolymer coated catalytic colloidal metal particles bound to a biomolecule such as an antibody, avidin, or streptavidin and kits containing such polymer or copolymer coated catalytic metal particles are useful for detecting the presence of the biomolecule in an assay such as an immunoassay.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: June 10, 1997
    Assignees: Geo-Centers, Inc., The United States of America as represented by the Secretary of the Navy
    Inventors: David A. Kidwell, Susan M. Conyers
  • Patent number: 5631172
    Abstract: The present invention relates to the field of immunoassays for metal ions. The invention presents: metal ion-ligand coordination complexes ("MLC"), novel ligands, antibodies specific for MLC, immunoassays utilizing the foregoing, and methods for selecting said antibodies.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: May 20, 1997
    Assignee: Abbott Laboratories
    Inventor: David K. Johnson
  • Patent number: 5631138
    Abstract: A method for the measurement of serum bile acids by ELISA comprising: preparing a bile acid active ester, reacting the ester with a bovine serum albumin solution, dialyzing, and immunizing a mammal other than human being with the dialyzate thus obtained as an antigen to thereby give an anti-bile acid antibody; reacting said active ester with an enzyme to thereby prepare an enzyme-labeled bile acid as an enzyme-labeled antigen; to a secondary antibody-coated plate, adding a dilution of the serum to be assayed, an anti-bile acid antibody solution and an enzyme-labeled antigen solution and reacting these substances followed by the addition of a substrate and the reaction therewith; measuring the absorbance of the reaction mixture and determining the concentration of each bile acid on the basis of the standard curve measured simultaneously; and referring the sum of the concentrations of these bile acids to the total bile acid concentration; and a method for the diagnosis of a liver disease comprising: calculating
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: May 20, 1997
    Assignee: Yuugengaisha B.S.R.
    Inventors: Motonari Kano, Masaru Matsumoto
  • Patent number: 5620902
    Abstract: The stereochemistry of sialylation of an acceptor saccharide to obtain an .alpha. (2-3) or .alpha. (2-6) linkage is controlled to favor the .alpha. anomer by use of an aromatic ester of the sialyl reagent. The resulting intermediate .alpha. (2-3) and .alpha. (2-6) sialylated intermediate disaccharide blocks are useful in the synthesis of antigenic substances which can be used to raise antibodies useful in diagnosis and therapy, and can themselves be used as reagents in various applications. The preparation of the tetrasaccharide antigens corresponding to the 19-9 and sialyl-X antigens characteristic of malignant tissue illustrates the application of this method.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: April 15, 1997
    Assignee: Alberta Research Council
    Inventors: Robert M. Ratcliffe, Andre P. Venot, S. Zaheer Abbas
  • Patent number: 5620857
    Abstract: Tightly focused beams of laser light are used as "optical tweezers" to trap and manipulate polarizable objects such as microspheres of glass or latex with diameters on the order of 4.5 .mu.m. When analytes are allowed to adhere to the microspheres, small quantities of these analytes can be manipulated, thus allowing their detection and quantitation even when amounts and concentrations of the analytes are extremely small. Illustrative examples include measuring the strength needed to break antibody-antigen bonds and the detection of DNA sequences.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 15, 1997
    Assignee: United States of America, as represented by the Secretary of Commerce
    Inventors: Howard H. Weetall, Kristian P. Helmerson, Roni B. Kishore
  • Patent number: 5610283
    Abstract: The present invention is directed to novel opiate derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the opiates and opiate metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: March 11, 1997
    Assignee: Biosite Diagnostics Incorporated
    Inventor: Kenneth F. Buechler
  • Patent number: 5599664
    Abstract: A method for observing and determining the size of individual particles and for determining the weight distribution of a sample containing particles of varying size, which involves placing a deformable or nondeformable particle in a medium, subjecting the particle to an external force, thereby causing conformational and/or positional changes, and then measuring these changes. Preferred ways to measure conformational and positional changes include: (1) determining the rate at which a deformable particle returns to a relaxed state after termination of the external force, (2) determining the rate at which a particle becomes oriented in a new direction when the direction of the perturbing force is changed, (3) determining the rate at which a particle rotates, (4) measuring the length of a particle, particularly when it is at least partially stretched, or (5) measuring at least one diameter of a spherical or ellipsoidal particle.
    Type: Grant
    Filed: December 7, 1993
    Date of Patent: February 4, 1997
    Assignee: New York University
    Inventor: David C. Schwartz
  • Patent number: 5599681
    Abstract: Activation-state-specific and protein-specific antiphosphoprotein antibodies and methods for their production are disclosed. Also disclosed are methods for evaluating the prognosis and therapeutic outcome for patients using the antiphosphoprotein antibodies and methods for characterizing the activation state of a reversibly phosphorylated protein, kits including the antibodies for use in characterizing the activation state of a protein, and methods for evaluating the agonist or antagonist activity of pharmaceutically useful compounds towards the conversion of a specific protein from its inactive to its active state.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: February 4, 1997
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Richard J. Epstein, Charles D. Stiles